Chronic Renal Failure Clinical Trial
Official title:
Using of the Skin as a Third Spare Kidney for Patients With Chronic Renal Failure
Using sweat as the vehicle for removing molecules normally excreted in the urine(dermodialysis) was identified some decades ago.The study will include 66 ESRD patients and 20 CKD stage 5 patients not on dialysis who met inclusion and exclusion criteria. The ESRD patients will be divided into three groups and will be subjected to different modalities of stimulation of sweating like infra-red sauna , physical exercise and hot bath. The study will be conducted over a period of three months. During the first month, patients were dialyzed as usual (control phase).During the next two months ,the participants will be dialysed twice weekly in addition to dermodialysis. S Cr, BUN, serum K and serum phosphorus will be measured weekly immediately before the last dialysis session during the control and intervention phases. The mean of this investigations during each phase will be calculated . The investigators will compare the mean of this investigations during control phase with the mean during the intervention phase to evaluate the effectiveness of dermodialysis as adjuvant therapy for ESRD patients.The patients not on dialysis will subjected to infra-red sauna and hot bath.The investigators also will compare the means of S Cr, BUN, serum K and serum phosphorus during both control and intervention phases like the ESRD patients.
Although dialysis has been considered as a life-saving treatment for end stage renal disease
(ESRD) patients, many ESRD patients in developing countries don't have access to dialysis
facilities . Using sweat as the vehicle for removing molecules normally excreted in the
urine(dermodialysis) was identified some decades ago. Sweat fluid mainly contains sodium
chloride, potassium, urea, ammonia, uric acid, and creatinine. The mean sweat fluid urea
concentration could reach 5.5 to 50 times the serum concentration . In particular, urea
concentrations in human sweat are persistently elevated in uremic patients . The 24-hour
urinary urea excretion in summer was as much as one-quarter of the quantity in winter in
uremic patients, indicating the compensatory urea excretion in sweat gland fluid .This high
level of urea and other toxic molecules crystallize out and deposit visibly on the skin when
the water of the sweat evaporates off ('uremic frost') .Sweat K concentration was
significantly higher in ESRD patients . Pruijm, El-Housseini et al reported that stimulated
sweating can be an effective way to reduce intradialytic weight gain(IDWG) in hemodialysis(
HD)patients. These findings indicated that dermodialysis can be used to delay the requirement
for and to reduce the frequency of dialysis and to improve the quality of lives of ESRD
patients especially in the developing World where economic and technical support barriers to
the provision of dialysis are present.
Sweating can be stimulated by many methods like physical exercise ,saunas and drugs like
pilocarpine. Traditional dry saunas use temperatures as high as 185 to 195 degrees F, which
is too much for some patients to tolerate. Infrared saunas use a much lower temperature (120
to 150 degrees F). However, because the heat of infrared saunas travels much deeper into the
body, they are able to cause a more vigorous sweat at lower temperature. Infrared sauna has
many benefits like normalizing blood pressure , treating congestive heart failure, weight
loss and relieving of chronic pain.
Head out water immersion was used many times in ESRD patients. Pruijm, El-Housseini et al
concluded that immersion in hot bath (temperature 37-43C) was effective method of stimulating
sweating and reducing IDWG. Intradialytic hypotension could be prevented by water immersion.
Primary objective:- Evaluation of feasibility of dermodialysis as adjuvant replacement
therapy for ESRD patients to decrease the cost of dialysis facilities (one third of the total
cost).
Secondary objectives:-
1. Improve uremic pruritus.
2. Better control of blood pressure.
3. Decrease interdialytic weight gain.
4. Comparing the effectiveness of infra-red sauna, exercise and combination of infra-red
sauna and head out water immersion as modality of dermodialysis The study will include
66 ESRD patients and 20 CKD stage 5 patients not on dialysis who met inclusion and
exclusion criteria. The ESRD patients will be subdivided into three group, each group
will include 22 patients .Each group will be subjected to Detailed history and Careful
examination. The study will be conducted over a period of three months(for each
patient). During the first month, patients will be dialyzed as usual (control phase).
Detailed information on blood pressure, interdialytic weight gain (IDWG), and dialysis
prescription will be recorded. S Cr, BUN, serum K and serum phosphorus will be measured
weekly immediately before the last dialysis session for one month and the mean will be
calculated. During the next two months the patient will be dialysed twice weekly on
Saturday and Wednesday. during the in-between three days(Sunday, Monday and Tuesday) the
three groups subjected to intervention as the following :- Group 1:-three session of
infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
Group 2:-three session of physical exercise of 20-30 minutes duration separated by 10 minutes
rest.
Group 3:-three session of infra-red sauna as the first group then the patients will be
immersed up to neck for one hour in water at 37-43 C.
Detailed information on IDWG, blood pressure, any improvement in uremic pruritus will be
recorded. Body temperature before and after the intervention will be measured and recorded.
Assessment of uremic pruritus according to verbal rating scale (VRS) which divided into four
level:-0=no symptom, 1=mild, 2= moderate, 3=sever or intense symptom. Dialysis prescription
and diet will be fixed as possible to be similar to the control phase.
S Cr, BUN, serum K and serum phosphorus will be measured weekly immediately before the last
dialysis session (Wednesday) for two months and the mean will be calculated. The patients
will be admitted in internal medicine department in the dialysis free period to be under
close observation. Dialysis will be done if there is urgent indication in the dialysis free
days.
The CKD group :- The patients will be subjected to Detailed history and Careful examination.
The study will be conducted over a period of three months. During the first month (control
phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be
calculated. During the next two months the patient will be subjected to three session of
sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the
patients will be immersed up to neck for one hour in water at 37 -43 C . Body temperature
before and after the intervention will be measured and recorded. During the intervention
phase, S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be
calculated. During the period of rest the patients will consume sufficient amount of water to
avoid dehydration .Blood pressure will be monitored and recorded. Dialysis will be done if
there is urgent indication or standard indication for dialysis according to KDOQI guide lines
2015.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 |